VERAXA Biotech Begins Trading on Nasdaq After Business Combination
VERAXA Biotech (VRXA) started trading on Nasdaq following a business combination with Voyager Acquisition Corp., advancing its oncology pipeline with proprietary BiTAC platform targeting solid tumors.
VERAXA Biotech (NASDAQ: VRXA) began trading on the Nasdaq Capital Market on June 11, 2026, following the successful conclusion of a business combination with Voyager Acquisition Corp. The company, which focuses on the discovery and development of antibody-based therapeutics for solid tumors, is now positioned to advance its diversified oncology pipeline.
VERAXA’s pipeline includes monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific ADCs, and proprietary BiTAC-based therapeutic formats across multiple cancer indications. The BiTAC platform is designed to conditionally activate therapeutic activity at tumor sites, aiming to improve target specificity while reducing off-tumor toxicity. This approach could address key limitations in current cancer therapies.
The company’s focus on ADCs and T-cell engagers (TCEs) places it within two rapidly growing segments of the global oncology therapeutics market. Through selected partnerships, VERAXA also aims to contribute to complementary therapeutic sectors such as radioimmunoconjugates (RICs) and antibody-oligonucleotide conjugates (AOCs).
The listing on Nasdaq marks a significant milestone for VERAXA, providing access to capital markets to fund its research and development efforts. The company’s vision is to deliver the next wave of smart cancer therapies with curative potential for patients with solid tumors.
Investors should note that forward-looking statements in this article involve risks and uncertainties, as detailed in the company’s filings with the SEC, including the forward-looking statements disclaimer. These factors may cause actual results to differ materially from those projected.